AR and prostate carcinoma: For example, the combination of olaparib with the androgen receptor (AR) inhibitors enzalutamide or bicalutamid is effective in HR-proficient prostate cancer due to suppression of HR gene expression (Asim et al. 2017; Li et al. 2017).